Skip to main content
Top
Published in: Arthritis Research & Therapy 5/2010

01-10-2010 | Letter

The influence of anti-cyclic citrullinated peptide on anticentromere antibody-positive rheumatoid arthritis patients

Authors: La-He Jearn, Think-You Kim

Published in: Arthritis Research & Therapy | Issue 5/2010

Login to get access

Excerpt

We read with interest the paper of Bournia and colleagues that anticentromere antibody (ACA)-positive primary Sjögren's syndrome (SS) shows a clinical phenotype intermediate between ACA-negative SS and systemic sclerosis (SSc) [1]. In our past study investigating the clinical features of 62 patients with positive ACA, only one patient had typical CREST syndrome, 9 patients had Raynaud's phenomenon (8 with sclerodactyly, telangiectasia or calcinosis), while rheumatoid arthritis (RA) was the most common diagnosis (21 patients) [2]. Thereafter, we investigated whether ACA-positive RA patients have distinctive clinical features compared to general RA patients [3] and found that the high titer group (over 1:320) was associated with Raynaud's phenomenon more often. This result suggests that RA patients are also affected by high titer ACA, similar to SS patients. …
Literature
1.
go back to reference Bournia V-KK, Diamanti KD, Vlachoyiannopoulos PG, Moutsopoulos HM: Anticentromere antibody positive Sjögren's syndrome: a retrospective descriptive analysis. Arthritis Res Ther. 2010, 12: R47-10.1186/ar2958.CrossRef Bournia V-KK, Diamanti KD, Vlachoyiannopoulos PG, Moutsopoulos HM: Anticentromere antibody positive Sjögren's syndrome: a retrospective descriptive analysis. Arthritis Res Ther. 2010, 12: R47-10.1186/ar2958.CrossRef
2.
go back to reference Kim KS, Kim TY, Kim SY: Diagnostic utility of anti-centromere antibody (I) [abstract]. Korean J Clin Pathol. 1994, 14 (Suppl): 104- Kim KS, Kim TY, Kim SY: Diagnostic utility of anti-centromere antibody (I) [abstract]. Korean J Clin Pathol. 1994, 14 (Suppl): 104-
3.
go back to reference Jearn LH, Kim TY: Clinical significance of anti-centromere antibody in rheumatoid arthritis. J Korean Rheum Assoc. 2004, 11: 159-164. Jearn LH, Kim TY: Clinical significance of anti-centromere antibody in rheumatoid arthritis. J Korean Rheum Assoc. 2004, 11: 159-164.
4.
go back to reference Morita Y, Muro Y, Sugiura K, Tomita Y: Anti-cyclic citrullinated peptide antibody in systemic sclerosis. Clin Exp Rheumatol. 2008, 26: 542-547.PubMed Morita Y, Muro Y, Sugiura K, Tomita Y: Anti-cyclic citrullinated peptide antibody in systemic sclerosis. Clin Exp Rheumatol. 2008, 26: 542-547.PubMed
Metadata
Title
The influence of anti-cyclic citrullinated peptide on anticentromere antibody-positive rheumatoid arthritis patients
Authors
La-He Jearn
Think-You Kim
Publication date
01-10-2010
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 5/2010
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3153

Other articles of this Issue 5/2010

Arthritis Research & Therapy 5/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine